Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...
Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types -- N17350 targets a cancer vulnerability, via the ...
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS ...
News-Medical.Net on MSN
New molecule offers a promising avenue to treat triple-negative breast cancer
A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable ...
The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...
Neoadjuvant therapy (NAT) for early breast cancer was first introduced in the 1980s to downstage large, inoperable tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback